The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Abstract
Objective: To study the specific effects of rituximab treatment on the synovium in patients with rheumatoid arthritis (RA) early after initiation of treatment. Methods: Seventeen RA patients underwent an arthroscopic synovial biopsy procedure directly before and 1 month after receiving 2 infusions of the chimeric anti‐CD20 monoclonal antibody rituximab (1,000 mg on days 1 and 15; both without methylprednisolone premedication). Immunohistochemical analysis was performed to characterize the cell infiltrate. Stained tissue sections were analyzed by digital image analysis. Statistical analysis was performed using Wilcoxon's signed rank test. Results: No significant change in the Disease Activity Score 28‐joint assessment was found at 4 weeks after the first rituximab infusion. At 2 and 4 weeks after infusion, B cells in peripheral blood were almost completely depleted. Most B cells in the synovium were found in large lymphocyte aggregates. Interestingly, a significant reduction in B cell numbers at sites of inflammation was observed 4 weeks after treatment (median 26 cells/mm 2 [interquartile range 4–150] before treatment and 11 cells/mm 2 [interquartile range 0–29] after treatment; P < 0.02). B cells disappeared completely in 3 patients, whereas there was partial depletion in 11 patients. In the other 3 patients, no B cells were present in biopsy tissues obtained either pretreatment or posttreatment. No reductions in other synovial cell populations were observed at 4 weeks. Conclusion: Rituximab treatment leads to a rapid and significant decrease in synovial B cell numbers, but not in all patients. Whether the variable tissue response is related to the clinical response over time remains to be clarified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Pathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationJones, R. B., Ferraro, A. J., Chaudhry, A. N., Brogan, P., Salama, A. D., Smith, K. G. C., Savage, C. O. S., & Jayne, D. R. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24637 · Cited by 350
Thurlings, R. M., Vos, K., Wijbrandts, C. A., Zwinderman, A. H., Gerlag, D. M., & Tak, P. P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080960 · Cited by 334
Self-citationB cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
Lafyatis, R., Kissin, E., York, M., Farina, G., Viger, K., Fritzler, M. J., Merkel, P. A., & Simms, R. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24249 · Cited by 288
Metadata
- Authors
- Vos, K., Thurlings, R. M., Wijbrandts, C. A., van Schaardenburg, D., Gerlag, D. M., & Tak, P. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-02-27
- Volume
- 56
- Issue
- 3
- Pages
- 772-778
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2059125686
- Cited by
- 194
- References
- 1
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.